This is the authors' abstract. We don't add key points for this paper.
Introduction: Acute hepatitis B infection resolves spontaneously in about 95% of the adults. Use of antivirals for acute hepatitis B infection is not needed in majority of patients with the exception of fulminant hepatic failure from acute hepatitis B infection or severe/protracted course of acute hepatitis B infection. Our goal was to evaluate factors associated with severe acute hepatitis B infection and to evaluate safety of tenofovir in the treatment of severe acute hepatitis B infection. Methods: We conducted a retrospective study using the University of Kentucky hospitals/clinics database. All patients (n=73) who were diagnosed with acute hepatitis B from 1/2010 to 12/2012 were reviewed. Data abstracted included age, race, gender, BMI, co-infection with HCV, HIV, mode of transmission, treatment with antiviral medications, outcome of acute hepatitis B infection, comprehensive metabolic panel, PT/INR, encephalopathy, patient survival, history of alcohol use, tobacco abuse, and liver transplantation. Results: Seventy-one subjects (median age of 40 years; range 26-76) participated in the study. Sixty-three (88.7%) were white and 36 (50.7%) were females. Sharing an infected needle was the most common mode of transmission in 74.6% of the cases. There was coinfection with hepatitis C in 28 subjects (39.4%). Acute hepatitis B resolved spontaneously in 61 patients (85.9% of the cases). However, 10 patients (9 females and 1 male) required treatment with antiviral therapy. Half of the patients were treated because they met 2 of the 3 criteria: hepatic encephalopathy, INR>1.6, and total bilirubin >10; the other half was treated because they presented with protracted, severe acute hepatitis B. Tenofovir was used to treat 9 patients whereas entecavir was used to treat 1 patient given the presence of acute kidney injury. The patient who was treated with entecavir expired due to multi-organ failure likely from sepsis. All patients treated with tenofovir were compliant with treatment, cleared the virus within 6 months, and developed hepatitis B surface antibody response. There was no incidence of major adverse events, including renal failure, in patients treated with tenfovir. Conclusion: Acute hepatitis B infection was more severe in females; 90% of the patients who require antiviral treatment for severe acute hepatitis in our study were females. Tenofovir is a safe drug to use in treating patients with severe acute hepatitis B with no significant adverse events reported at 6 months of follow-up.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: